| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Cancer Antigen 125
Test CodeCA25F
Alias/See Also
CA 125, Cancer Antigen, CA125, 125
CPT Codes
86304
Preferred Specimen
Light Green (PST)
Other Acceptable Specimens
Serum (Red) or Gold (SST) or Orange (OJ) or Tiger Top Serum
Instructions
Allow serum samples to clot completely before centrifugation.
Keep tubes stoppered at all times.
Within two hours after centrifugation, transfer at least 500 microliters of cell-free sample to a storage tube and tightly stopper.
Keep tubes stoppered at all times.
Within two hours after centrifugation, transfer at least 500 microliters of cell-free sample to a storage tube and tightly stopper.
Specimen Stability
Store samples tightly stoppered at room temperature (15-30°C) for no longer than eight hours.
If the assay will not be completed within eight hours, refrigerate the samples at 2-8°C.
If the assay will not be completed within 48 hours, or for shipment of samples, freeze at -20°C or colder. Thaw samples only once.
If the assay will not be completed within eight hours, refrigerate the samples at 2-8°C.
If the assay will not be completed within 48 hours, or for shipment of samples, freeze at -20°C or colder. Thaw samples only once.
Methodology
Beckman DXI
Setup Schedule
24x7
Reference Range
0-35 U/mL
Clinical Significance
Ovarian cancer is one of the most common types of gynecological malignancies, and the fourth most frequent cause of cancer death in women. Ovarian cancer tends to be asymptomatic in its earliest, more curable stages, and many patients have widespread disease at the time of discovery. Some favorable prognostic factors include younger age, lower stage, well-differentiated tumor, and small disease volume prior to surgery.
CA-125 antigen levels have no proven prognostic value when used for either screening or at time of diagnosis. However, CA-125 antigen levels do correlate with patient status after initial treatment.
Serum CA-125 antigen levels may be used as an aid in monitoring the response to therapy for patients with epithelial ovarian carcinoma. The presence of persistently rising CA-125 antigen levels may be correlated with disease progression. Persistently elevated CA-125 antigen levels indicate poor response to therapy, whereas decreasing CA-125 antigen levels may indicate a positive therapeutic response.
CA-125 antigen levels are elevated in many patients with epithelial ovarian carcinoma. It may also be elevated in diseases other than epithelial ovarian carcinoma, including other benign or malignant ovarian diseases, such as endometriosis, and in lung cancer and in other non-cancerous conditions such as pregnancy.
CA-125 antigen levels have no proven prognostic value when used for either screening or at time of diagnosis. However, CA-125 antigen levels do correlate with patient status after initial treatment.
Serum CA-125 antigen levels may be used as an aid in monitoring the response to therapy for patients with epithelial ovarian carcinoma. The presence of persistently rising CA-125 antigen levels may be correlated with disease progression. Persistently elevated CA-125 antigen levels indicate poor response to therapy, whereas decreasing CA-125 antigen levels may indicate a positive therapeutic response.
CA-125 antigen levels are elevated in many patients with epithelial ovarian carcinoma. It may also be elevated in diseases other than epithelial ovarian carcinoma, including other benign or malignant ovarian diseases, such as endometriosis, and in lung cancer and in other non-cancerous conditions such as pregnancy.
Performing Laboratory
CRMC Laboratory
